Dan Nardi, CEO
Across healthcare, talented teams are working to transform the cancer experience. Advances in artificial intelligence are enabling more personalized treatment decisions. Digital tools are expanding access to care in rural communities. Breakthrough therapies like CAR T-cell treatment are turning once-terminal diagnoses into survivable conditions.
At Reimagine Care, we’re proud to contribute to this momentum by using technology to make cancer treatment more accessible, effective, and patient-centered.
But just as these innovations are gaining ground, research funding is being cut.
The Consequences Are Real
When research budgets are reduced, the impact goes far beyond the academic community. It means an AI-powered platform that could detect treatment complications early may never make it out of the lab. It means a predictive algorithm designed to match patients with the right therapy might remain unvalidated and unused.
Every major advancement in cancer care—from targeted therapies to precision medicine—has been built on a foundation of sustained research investment. The same holds true for the tools we are developing at Reimagine Care. Our remote monitoring platforms, AI-driven symptom support, and virtual care models are designed to transform how care is delivered. But these solutions will only reach the patients who need them most if we continue investing in the research required to validate and implement them at scale.
Why It Matters Beyond the Lab
Our work with health systems across the country consistently highlights a core truth. The most promising technologies often serve those who are least well supported by traditional care models. These include patients in underserved rural areas, older adults who may not be able to travel for appointments, and working families trying to manage treatment alongside daily responsibilities.
These populations may not represent the most commercially attractive markets, which makes them less likely to be prioritized by private investment alone. This is where public and nonprofit research funding plays a critical role. It enables the essential work of validating whether a tool truly improves outcomes, testing solutions across diverse populations, and building the evidence needed to make innovations part of standard care rather than costly exceptions.
A Shared Responsibility
This is a challenge we can meet if we move with urgency and purpose:
- For policymakers: Research funding is not just a line item in the budget. It is an investment in better patient outcomes and lower long-term healthcare costs.
- For healthcare leaders: Advocate for payment models that support innovative approaches to care delivery. When digital tools are reimbursed appropriately, adoption becomes faster and more widespread.
- For patients and families: When possible, consider participating in research efforts. Real-world data is what transforms early results into solutions that work for everyone.
- For companies like Reimagine Care: We must embed research into our core operations. It is not enough to build promising tools. We must also prove that they work, and we are committed to doing just that.
The Stakes
The difference between hope and despair often comes down to access. Patients need the right care, the right tools, and the right information at the right time. The technologies being developed today have the potential to make personalized, proactive, AI-supported cancer care a routine part of the patient experience.
This vision is possible, but only if we continue investing in the research that brings these technologies to life and ensures they reach the people who need them most.
Looking Ahead
Cancer research has always been about pushing the boundaries of what is possible. Advances that once seemed unimaginable have become standard practice. But none of that progress happens without sustained commitment to discovery, validation, and implementation.
We are standing at a crossroads. We can choose to protect and expand the funding that makes innovation possible. Or we can allow short-term budget decisions to stall progress at a moment when the future of cancer care is finally within reach.
The patients we serve—both today and in the future—deserve our continued focus, investment, and belief in what is possible.
Now is the time to act.